Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
FibroBiologics, Inc. ( (FBLG) ) has issued an update.
On August 4, 2025, FibroBiologics, Inc. was notified by Nasdaq that its market value of listed securities had fallen below the required $35 million minimum for 30 consecutive trading days, triggering a 180-day grace period through February 2, 2026, to regain compliance. On February 3, 2026, Nasdaq staff issued a formal notice that the company’s continued non-compliance with the market value rule now constitutes an additional basis for delisting, alongside a previously disclosed bid price deficiency. The matter is currently before a Nasdaq Hearings Panel, which will review FibroBiologics’ plan to restore compliance, and the company’s stock will remain listed and trading at least until the panel issues a decision and any potential extension expires. As part of its efforts, FibroBiologics filed definitive proxy materials on December 29, 2025, seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30, although there is no assurance the company will obtain an extension or successfully meet the listing standards, leaving investors facing ongoing uncertainty over the firm’s Nasdaq listing status.
The most recent analyst rating on (FBLG) stock is a Hold with a $0.27 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.
Spark’s Take on FBLG Stock
According to Spark, TipRanks’ AI Analyst, FBLG is a Neutral.
The score is primarily constrained by weak financial fundamentals (no revenue, widening losses, higher cash burn) and an increasingly risky capital structure. Technicals are mixed with only modest near-term momentum and a weaker longer-term trend, while valuation provides little support due to negative earnings. Added downside risk comes from the Nasdaq delisting/reverse-split situation.
To see Spark’s full report on FBLG stock, click here.
More about FibroBiologics, Inc.
FibroBiologics, Inc. is a publicly traded company listed on the Nasdaq Capital Market, with its securities subject to Nasdaq’s continued listing standards, including minimum bid price and market value of listed securities requirements.
Average Trading Volume: 2,046,109
Technical Sentiment Signal: Sell
Current Market Cap: $16.64M
For detailed information about FBLG stock, go to TipRanks’ Stock Analysis page.